26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)

التفاصيل البيبلوغرافية
العنوان:	26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)
المؤلفون:	Huber, V., Mereu, A., Lalli, L., Salsetta, J., Banfi, C., Squarcina, P., Sgambelluri, F., Mortarini, R., Stellato, M., Raggi, D., Guadalupi, V., Claps, M., Ferrari Bravo, W., Calareso, G., Alessi, A., Anichini, A., Procopio, G., Necchi, A., Rivoltini, L., Giannatempo, P.
المصدر:	In Immuno-Oncology and Technology December 2023 20 Supplement
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	25900188
DOI:	10.1016/j.iotech.2023.100495